Author: Ravi Shankar

• In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44
• In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at Week 44
• Duvakitug was well tolerated and safety was consistent with the induction study

PARSIPPANY, N.J. and PARIS, Oct. 20, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension (LTE) study (clinical trial identifier: NCT05668013) in patients with moderately-to-severely active ulcerative colitis (UC) or Crohn’s disease (CD), which demonstrated that duvakitug maintained clinically meaningful efficacy improvements across multiple endpoints over 44 weeks. Duvakitug is an investigational human monoclonal antibody that targets TL1A, a protein that amplifies inflammation and potentially drives fibrosis in UC and CD.

In addition, biomarker findings that advance the understanding of how duvakitug may impact inflammation and tissue remodeling in inflammatory bowel disease (IBD) were shared. These data were presented today at United European Gastroenterology (UEG) Week 2026 in Barcelona.

The RELIEVE UCCD LTE study evaluated the efficacy, safety, and tolerability of duvakitug through 44 weeks of maintenance treatment after induction in patients with UC and CD, the two most common forms of IBD. Patients (n=130, 72 with UC and 58 with CD) who responded to duvakitug treatment in the 14-week induction study were randomized to receive either duvakitug 450 mg or 900 mg subcutaneously every four weeks (Q4W) for up to 58 weeks of total exposure.

UC Results
At Week 44, maintenance treatment with duvakitug demonstrated high rates of clinical remission and clinical response, as measured by the modified Mayo Score (mMS), meaning active UC symptoms such as rectal bleeding, increased stool frequency, and pain have stopped (remission) or improved (response). Duvakitug treatment also achieved high rates of endoscopic improvement, defined by a Mayo Endoscopic Score of 0 (inactive disease in the colon) or 1 (mild disease activity), which measures the presence and degree of intestinal inflammation. Efficacy outcomes were numerically higher at 900 mg compared to 450 mg, consistent with a dose response. 

Efficacy in UC at Week 44 Maintenance Phase Endpoint
	Duvakitug 450 mg Q4W [n=34]	Duvakitug 900 mg Q4W [n=38]
Clinical remission (mMS)	47% [95% CI: 30, 65]	58% [95% CI: 42, 73]
Clinical response (mMS)	82% [95% CI: 61, 91]	87% [95% CI: 71, 94]
Endoscopic improvement	59% [95% CI: 42, 76]	63% [95% CI: 47, 78]
Data are descriptive. Confidence intervals (CIs) are based on logistic regression.

“Ulcerative colitis can have a significant impact on patients that disrupts even the most basic daily activities. Despite available therapies, some patients continue to experience flares that impact their lives in various ways and may contribute to disease progression,” said Walter Reinisch, MD, PhD, Director of the Inflammatory Bowel Disease Study Group at the Medical University of Vienna and a co-lead investigator of the RELIEVE UCCD LTE study. “These results underscore the potential of duvakitug to deliver effective and durable relief from persistent inflammation and symptoms, supporting better long-term disease management in patients with ulcerative colitis.”

CD Results
Duvakitug maintenance treatment demonstrated high rates of endoscopic response, defined as a 50% or more decrease from baseline in Simple Endoscopic Score for Crohn’s Disease (SES-CD) at Week 44. SES-CD assesses mucosal ulcers, the ulcerated surface, the endoscopic extension, and the presence of stenosis in the colon as a gauge of disease severity. Additionally, duvakitug maintained high rates of clinical response and clinical remission as measured by the Crohn’s Disease Activity Index (CDAI), meaning symptoms such as abdominal pain, diarrhea, and fatigue have stopped (remission) or improved (response). Duvakitug appeared to demonstrate a dose response, with numerically higher efficacy results achieved at the higher dose. 

Efficacy in CD at Week 44 Maintenance Phase Endpoint
	Duvakitug 450 mg Q4W [n=27]	Duvakitug 900 mg Q4W [n=31]
Endoscopic response	41% [95% CI: 25, 62]	55% [95% CI: 39, 75]
Clinical response (CDAI)	81% [95% CI: 63, 94]	87% [95% CI: 70, 96]
Clinical remission (CDAI)	81% [95% CI: 65, 95]	84% [95% CI: 68, 96]
Data are descriptive. Confidence intervals (CIs) are based on logistic regression.

“Due to the heterogeneous nature of Crohn’s disease, many patients either stop responding or never respond to available therapies, leaving them with uncontrolled symptoms that cause physical distress,” said Vipul Jairath, MBChB, DPhil, FRCP, FRCPC, Professor of Medicine in the Departments of Medicine, Epidemiology and Biostatistics at Western University and a co-lead investigator of the RELIEVE UCCD LTE study. “The efficacy rates seen with duvakitug in the maintenance period highlight its potential as a new treatment option that could help more patients achieve sustained remission.”

Across both UC and CD, duvakitug was generally well tolerated throughout the maintenance period, with a safety profile consistent with the induction phase and no new safety concerns identified. The most frequently reported adverse events (AEs) occurring in ≥5% of patients across pooled duvakitug dose groups in UC were upper respiratory tract infection and nasopharyngitis, and in CD were upper respiratory tract infection, CD, hypertension, nasopharyngitis, anemia, and influenza. The majority of AEs were mild or moderate in severity. Discontinuation rates due to AEs were low (UC, 4% and 2% in the 450 mg and 900 mg arms, respectively, and in CD were 6% in each arm).

Biomarker Results
Biomarker analyses from the RELIEVE UCCD induction study (clinical trial identifier: NCT05499130) were presented at UEG Week 2026. Duvakitug reduced blood levels of markers connected to multiple inflammatory pathways in UC and to the Th17 and Th1 immune pathways in CD, as well as markers of neutrophilic inflammation in both blood and tissue in CD and UC. In patients with CD, duvakitug also reduced markers of tissue remodeling. These findings provide additional mechanistic evidence that TL1A inhibition may address both inflammation and, potentially, fibrosis.

Additionally, clinical results from the RELIEVE UCCD induction study were recently published in The Lancet Gastroenterology and Hepatology for UC and CD.

Duvakitug Clinical Development Program
Duvakitug is being investigated in the phase 3 SUNSCAPE-1 (clinical trial identifier: NCT07184996) and SUNSCAPE-2 (clinical trial identifier: NCT07185009) studies in moderately-to-severely active UC, and the phase 3 STARSCAPE-1 (clinical trial identifier: NCT07184931) and STARSCAPE-2 (clinical trial identifier: NCT07184944) studies in moderately-to-severely active CD. Sanofi and Teva have initiated the phase 2 AURALIGHT study (clinical trial identifier: NCT07812116) of duvakitug in moderate-to-severe hidradenitis suppurativa and are planning a phase 2 study of duvakitug in fibrostenotic Crohn’s disease.

Duvakitug is currently under clinical investigation, and its efficacy and safety have not been evaluated by any regulatory authority.

About IBD
Inflammatory bowel disease (IBD) is an autoimmune disorder characterized by chronic inflammation of the gastrointestinal (GI) tract. Globally, approximately 4.9 million cases of IBD have been identified, with incidence rising in several regions. The two main types of IBD are ulcerative colitis (UC) and Crohn’s disease (CD), which are characterized by repetitive cycles of relapses and remission. Common symptoms of both conditions include persistent diarrhea, rectal bleeding, abdominal pain, loss of appetite, and weight loss.

Prolonged inflammation can lead to damage within the GI tract, including fibrosis, a common complication of IBD characterized by an excessive accumulation of scar tissue in the intestinal wall, which may cause narrowing and obstruction.

Currently, there is no cure for IBD. The goal of current treatment is to induce and maintain remission and prevent flares.

About the RELIEVE UCCD phase 2b program
The RELIEVE UCCD program is comprised of an induction study and a long-term extension (LTE).

RELIEVE UCCD: A 14-week phase 2b, randomized, double-blinded, dose-ranging induction study to evaluate the efficacy, safety, pharmacokinetics, and tolerability of duvakitug in adults with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD). The study was an innovative and efficient basket study design allowing the inclusion of patients with either UC or CD. It is the first and only randomized, blinded and placebo-controlled phase 2 study to investigate the impact of TL1A inhibition in CD.

RELIEVE UCCD LTE: An ongoing phase 2b study to evaluate the long-term efficacy and safety of duvakitug. Patients who received duvakitug, completed the 14-week induction study, and were responders, entered a 44-week double-blind maintenance period and were re-randomized to receive either 450 mg or 900 mg of subcutaneous duvakitug every four weeks. Patients who completed the 44-week maintenance period may continue to receive duvakitug in an open-label extension.

Primary efficacy endpoints for both the 14-week induction study and the 44-week maintenance period are clinical remission (as defined by mMS) in the UC cohort or endoscopic response (as defined by SES-CD) in the CD cohort. The study includes sites in the US, Europe, Israel, and Asia.

About duvakitug 
Duvakitug is a human monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A) being developed to reduce inflammation and potentially fibrosis. Duvakitug is currently in phase 3 clinical studies for the treatment of ulcerative colitis and Crohn’s disease and is also being investigated in hidradenitis suppurativa and fibrostenotic Crohn’s disease. The safety and efficacy of duvakitug have not been reviewed by any regulatory authority.

About the Sanofi and Teva collaboration
Sanofi and Teva are collaborating to co-develop and co-commercialize duvakitug for the treatment of ulcerative colitis and Crohn’s disease, as well as fibrostenotic Crohn’s disease and hidradenitis suppurativa. Each company will equally share the development costs globally, and the net profits and losses in major markets, with other markets subject to a royalty arrangement. Teva will lead commercialization of the product in Europe, Israel, and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia, and the rest of the world.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop duvakitug for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD) as well as fibrostenotic Crohn’s disease and hidradenitis suppurativa; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; financial, economic and other risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. 

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Sanofi forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,”  or the negative of these, and similar expressions are intended to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S. Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation;  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Considering these risks, uncertainties, and assumptions, you should not place undue reliance on any forward-looking statements contained herein.

Teva Media Inquiries:
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries:
TevaIR@Tevapharm.com

Sanofi Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com 
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com 
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com 
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com 

Sanofi Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com 
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com 
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com 
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com  
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com 
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

WISeSat.Space and SEALSQ Advance Satellite Cybersecurity Hardening as FOSSA Launches New 6U Satellite Aboard SpaceX Falcon 9

This new FOSSASAT-2E27 launch expands opportunities for rigorous in-orbit testing of WISeSat SEALSQ security technologies to strengthen satellite resilience against emerging cyber and quantum threats

Longstanding strategic partnership, supported by successive investments, targets further technology validation across up to six satellite missions as demand for quantum-resistant security is expected to accelerate

GENEVA, Switzerland, October 20, 2026 — WISeSat.Space Holdings Corp. (Nasdaq: SAIQ) (“WISeSat.Space” or “WISeSat”) today announced a new milestone in its secure space infrastructure strategy, following the successful launch and deployment of FOSSASAT-2E27, a new-generation 6U satellite developed and operated by its longstanding strategic partner FOSSA Systems (“FOSSA”), aboard SpaceX’s Falcon 9 Bandwagon-5 mission from Cape Canaveral, Florida.

Equipped with VaultIC secure-element technology from SEALSQ Corp. (Nasdaq: LAES), the spacecraft provides a further opportunity to advance WISeSat’s technology-validation roadmap, building on years of cooperation to integrate hardware-based cybersecurity into satellite systems.

The mission illustrates the value of a strategic industrial relationship established in 2021 through WISeQey Corp’s (SIX/Nasdaq: WQEY) original investment in FOSSA and reinforced by WISeSat’s participation in FOSSA’s latest financing round in June 2026.

Under an extended technical collaboration covering up to six selected FOSSA satellite missions, WISeSat and FOSSA intend to pursue more systematic and demanding in-orbit testing protocols for SEALSQ security technologies, including repeatable functional testing, performance monitoring and analysis under actual space operating conditions.

The collaboration is expected to support the progressive validation of VaultIC secure elements and, subject to technical readiness and integration, the next-generation QS7001 post-quantum secure element. Selected experiments are intended to include six-month in-orbit testing and monitoring periods, generating technical data to inform future satellite security architectures.

Positioning for Growing Post-Quantum Security Requirements

The expanded collaboration comes as governments and critical infrastructure operators prepare for the transition toward quantum-resistant cybersecurity. In particular, U.S. Executive Order 14412, issued on June 22, 2026, establishes an accelerated framework for federal migration to post-quantum cryptography, including requirements scheduled for implementation from 2030 onward.

WISeSat believes that building practical flight heritage and strengthening in-orbit validation today will be important to addressing future requirements for trusted satellite communications, including sovereign, defense and critical-infrastructure applications.

Carlos Moreira, CEO of WISeSat.Space, commented: “Building quantum-resilient space infrastructure requires a clear path from technology development to demonstrated performance in orbit. This planned mission represents the next step in that process by providing another platform to evaluate SEALSQ’s security technologies under real operating conditions. Through our collaboration with FOSSA, we aim to apply what we learn from today’s testing to future satellite systems, while preparing for the integration and validation of next-generation post-quantum security.”

Gwenaël Rouy-Poirier, Group CFO of WISeSat.Space, added: “This launch is a strong illustration of how we intend to execute our strategy: leveraging long-term industrial partnerships and targeted investments to accelerate technology development and validation while maintaining capital discipline. As governments and critical infrastructure operators prepare for the transition to post-quantum security, reinforced by the recent White House Executive Order, we believe that demonstrated performance in orbit will become an increasingly valuable differentiator. Our collaboration with FOSSA allows us to continue building that evidence today, as we prepare for the next generation of WISeSat infrastructure and the commercial opportunities we expect to emerge.”

Julián Fernández, CEO and Co-founder of FOSSA Systems, commented: “Our relationship with WISeSat goes well beyond individual satellite launches. We have worked together for several years to bring advanced semiconductor security technologies into space, and our new 6U platform creates further opportunities to expand that work. With the next phase of our collaboration, we intend to move toward more systematic in-orbit testing and validation, building the technical experience required for increasingly sophisticated secure satellite applications.”

The FOSSASAT-2E27 mission also incorporates software-defined radio capabilities, onboard AI processing and a separate electric-propulsion demonstration, reflecting the technological evolution of FOSSA’s satellite platforms.

The collaboration complements WISeSat’s broader roadmap to develop next-generation, quantum-resilient orbital infrastructure intended to support SEALSQ’s planned Quantum Spatial Orbital Cloud (QSOC) and other secure communications applications.

About FOSSA Systems

FOSSA Systems is a Spain-based aerospace company specializing in small-satellite development, launch and operations, providing space infrastructure for communications and related applications. Visit fossa.systems

About WISeSat.Space

WISeSat.Space Holdings Corp. (Nasdaq: SAIQ) is a space technology company focused on secure satellite communications and related space infrastructure. Its approach combines satellite infrastructure with cybersecurity and digital identity technologies to support trusted communications between connected devices and ground-based systems. WISeSat.Space intends to provide satellite capacity and related space and ground infrastructure that may support SEALSQ’s planned QSOC roadmap. Visit wisesat.space

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding estimation of the listing. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of WISeSat’s management and are not predictions of actual performance. These statements involve risks, uncertainties and other factors that may cause the actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although WISeSat believes that it has a reasonable basis for each forward-looking statement contained in this press release, WISeSat cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. The forward-looking statements in this press release represent the views of WISeSat as of the date of this press release. Subsequent events and developments may cause those views to change. Except as may be required by law, WISeSat does not undertake any duty to update these forward-looking statements.

CONTACTS

WISeSat:
Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
info@wisesat.com

WISeSat Investor Relations:
The Equity Group Inc.
Lena Cati
Tel: +1 212 836-9611
Lena.cati@theequitygroup.com

Transactions during 13 October 2026 – 19 October 2026
On 7 May 2026, Alm. Brand A/S announced a share buy-back program of up to DKK 593 million, as described in company announcement no. 23/2026.

The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.

The following transactions were made under the share buy-back program 13 October – 19 October 2026:

	Number of shares bought	Average purchase price	Amount (DKK)
Accumulated, last announcement 13 October 2026 14 October 2026 15 October 2026 16 October 2026 19 October 2026	16,272,795 330,000 200,000 311,000 303,000 350,000	16.44 16.77 16.77 16.95 16.97 17.11	267,545,385 5,534,562 3,354,700 5,272,134 5,142,455 5,987,625
Total, 13 October – 19 October 2026	1,494,000	16.93	25,291,477
Accumulated under the program	17,766,795	16.48	292,836,862

With the transactions stated above Alm. Brand A/S holds a total of 50,503,465 own shares, corresponding to 3.59% of the total number of outstanding shares.

Contact
Please direct any questions regarding this announcement to:

Investors and equity analysts:                 

VP, Head of Investor Relations & ESG        
Mads Thinggaard                 
Mobile no, +45 2025 5469                

Attachments

• Alm Brand_Share buyback 13 October – 19 October 2026
• AS 57 2026 – Transactions under share buyback program

October 20, 2026

Advanced reporting and workflow capabilities developed by MediReport are expected to complement Philips’ cardiovascular informatics portfolio and support its evolution toward a more connected, AI-enabled and cloud-ready cardiovascular experience. 

Amsterdam, the Netherlands – October 20, 2026 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how advanced reporting and workflow capabilities developed by MediReport are expected to complement its cardiovascular informatics portfolio and support its broader Integrated Diagnostics vision ahead of Transcatheter Cardiovascular Therapeutics (TCT) 2026.  

Philips brings together expertise in diagnostic and interventional cardiology, image-guided therapy and informatics to support cardiovascular care, from diagnosis through intervention and follow-up. As part of its presence at TCT, Philips will showcase innovations that support clinical confidence, streamline workflows and make meaningful information easier to access, while engaging with customers and clinical leaders on opportunities to better connect diagnostic and interventional care.  

Cardiovascular teams often work across separate imaging, hemodynamic, documentation and reporting systems. This can require repeated data entry and delay access to the complete clinical information needed for procedure reporting, coding and follow-up.  

In Philips’ Future Health Index 2025: Cardiology Snapshot, 79% of cardiac care professionals surveyed reported losing clinical time because patient data was incomplete or inaccessible. Almost half of this group reported losing more than 45 minutes per shift [1]. These findings underline the need to make clinical information easier to capture, access and reuse across the care pathway. 

Following the acquisition of MediReport, Philips expects to strengthen its cardiovascular informatics capabilities. MediReport 360 supports structured cardiovascular documentation and real-time reporting at the point of care, with guided workflows before, during and after procedures. It enables health systems to capture clinical information once and reuse it across physician and nursing reports, coding, registries, analytics, charge capture and follow-up. MediReport’s technologies support cloud and on-premises deployment, with vendor-neutral interfaces to imaging systems, hemodynamic systems and hospital IT.   

This expected enhancement would build on Philips’ existing cardiology informatics portfolio, including Cardiovascular Workspace for image and information management, with cloud deployment available in North America; Ultrasound Workspace for ultrasound review, analysis and reporting; and interventional solutions supporting cath-lab information management and hemodynamic workflows.  

“Clinicians need technology that fits the way they work and gives them more time for patient care”, said Madhuri Sebastian, Business Unit Leader Imaging Informatics at Philips. “The capabilities developed by MediReport complement Philips’ strengths in cardiovascular imaging, hemodynamics and enterprise informatics. Together, they are expected to simplify how information moves across cardiac care, enabling a more connected experience for care teams. This would also support Philips’ longer-term direction towards cloud-ready, AI-enabled cardiovascular and integrated diagnostics workflows.”  

Visit Philips at TCT 2026 to explore innovations in imaging, physiology, procedural guidance and cardiovascular informatics that help care teams access meaningful information and simplify reporting and workflows.

[1] Philips Future Health Index 2025: Cardiology Snapshot — Building trust in AI for cardiac care. 

For further information, please contact:

Name Jayme Maniatis
Philips Global External Relations
Tel.: +16178948368
E-mail: name.here@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Philips cardiology informatics at TCT

Recognition highlights company’s FDA-cleared AI technology combining pulmonary nodule detection and diagnosis to aid radiologists in lung cancer diagnosis

SAN FRANCISCO, CA and SOPHIA ANTIPOLIS, France, Oct. 20, 2026 (GLOBE NEWSWIRE) — Eyonis Inc., a Median Technologies company focused on applying artificial intelligence to the early detection and diagnosis of cancer, today announced that it has been named a Rising Star finalist in the Cancer, Screening & Early Detection category of the 2026 Digital Health Hub Foundation Digital Health & AI Awards.

Selected from a field of more than 1,300 submissions, the finalists represent companies developing technologies with the potential to improve healthcare. The prestigious annual awards recognize innovation across digital health, including cancer screening, diagnostics, disease prevention and care delivery.

Eyonis was recognized for its work advancing AI-powered lung cancer screening, including the development of eyonis® LCS, the first FDA-cleared AI-powered solution to both detect pulmonary nodules and assess their likelihood of malignancy on low-dose CT scans to aid radiologists in lung cancer diagnosis.

The recognition comes as healthcare providers look for ways to expand lung cancer screening while improving the accuracy of screening results. Low-dose CT scans can reveal potentially cancerous nodules before symptoms develop, but finding a nodule is only the beginning. Radiologists working with pulmonologists must also assess a nodule’s likelihood of malignancy to help decide whether it needs further diagnostic work-up or prolonged surveillance, which can lead to patient anxiety and difficult decisions about whether to recommend a potentially dangerous invasive biopsy.

eyonis® LCS addresses both stages of that process, supporting the detection of suspicious pulmonary nodules and the assessment of their likelihood of malignancy from low-dose CT examinations. By bringing detection and diagnosis into a single lung cancer screening workflow for the first time, the technology addresses one of the most significant challenges in lung cancer care—helping clinicians identify cancer earlier with greater diagnostic confidence.

“Lung cancer screening has enormous potential to save lives, but detecting more nodules doesn’t necessarily mean finding more cancer,” said Oran Muduroglu, President of Eyonis. “Clinicians need to know which findings are most concerning and which patients may need additional evaluation. We developed eyonis LCS to help answer that question. Being named a Rising Star finalist recognizes our team’s work to move beyond detection and give clinicians more meaningful diagnostic information.”

eyonis® LCS has demonstrated[i] sensitivity of 93.3%, specificity of 92.4%, and a 99.9% negative predictive value.  With eyonis® LCS supporting, this translates into radiologists improving sensitivity by 13 percentage points and specificity by 16 percentage points, while reducing false negatives by 66% and false positives by 68%.[ii] [iii]

These findings suggest that combining radiologists’ clinical expertise with AI assistance offers the potential to match or even surpass the software’s standalone diagnostic performance. The results also demonstrate the software’s ability to aid clinicians in identifying patients with lung cancer while minimizing false positive results that may lead to unnecessary and costly additional imaging or invasive procedures.

The winners of the 2026 Digital Health & AI Awards will be announced Nov. 16 at the 2026 HLTH conference in Las Vegas.

About Eyonis

Eyonis, a Median Technologies company, markets a suite of AI-powered Software as a Medical Device (SaMD) designed to improve the early detection and diagnosis of cancer. Its flagship product, eyonis® LCS, analyzes low-dose CT examinations to support both the detection of suspicious lung nodules and the assessment of their likelihood of malignancy within the lung cancer screening workflow. eyonis® LCS received FDA clearance in the United States in February 2026 and CE marking in Europe in July 2026. To learn more, visit https://eyonis.ai.

About Median Technologies

Median Technologies provides AI-powered medical imaging solutions for cancer diagnosis, treatment and drug development. The company operates through two businesses: Eyonis, which develops AI-powered Software as a Medical Device for cancer detection and diagnosis, and iCRO, which provides imaging services for oncology clinical trials. Headquartered in France with operations in the United States and China, Median Technologies is listed on Euronext Growth Paris under the ticker ALMDT. To learn more, visit https://mediantechnologies.com/ 

---

[i] Manufacturer Values, Median Technologies data on file.

[ii] Estimated from Jonas DE, et al. JAMA. 2021 Mar 9;325(10):971-987

[iii] RELIVE MRMC (Multi-Reader Multi-Case) Study, ClinicalTrials.gov ID: NCT06751576.

Attachment

• Digital Health & AI Award Badge

CONTACT: Todd Stein
eyonis
5104170612
todd@toddsteincommunications.com

WUHU, China, Oct. 20, 2026 (GLOBE NEWSWIRE) — From October 19 to 23, the 2026 Chery International User Summit is bringing together users, media representatives and ecosystem partners from around the world in Wuhu. Under the theme “HIGH TECH FOR OUR FUTURE LIFE”, the summit will explore the future of intelligent, low-carbon and sustainable mobility and lifestyles.

During the summit, Chery Auto will showcase advances in green energy manufacturing, intelligent charging and Robotaxi technology, while AiMOGA Robotics will demonstrate intelligent services through live interactions. From charging and autonomous driving to robotics, technology is making everyday life more convenient. As mobility expectations evolve beyond reaching a destination, comfort and quality of life are gaining importance. Through interactive experiences and global user exchanges, the summit will explore how technology can enrich daily life and connect brands with users.

As Chery Auto’s Premium NEV brand, LEPAS responds to users’ expectations for distinctive design, intelligent convenience and comfort through its three core pillars: Leopard Aesthetics, Elegant Technology and Exquisite Space. As LEPAS launches and delivers its NEV lineup worldwide, users are experiencing these pillars firsthand. From first impressions of a vehicle’s exterior and cabin in the showroom to daily commutes and longer journeys, users are discovering what “Drive Your Elegance” means through everyday driving experiences.

As these experiences reach different markets, local tastes, road conditions and ways of life shape different perspectives on elegance. The summit brings these experiences and personal stories together in Wuhu, giving LEPAS and its global users an opportunity to exchange ideas and collaborate in person.

On October 18, LEPAS launched its inaugural Global Elegant Lifestyle Week. The first LEPAS owners, partners, industry media and Global Elegant Lifestyle Partners from different regions began arriving in Wuhu for the event, held under the theme “TOGETHER IN ELEGANCE.”

During the week, participants will explore elegance through four dimensions: design, technology, driving and lifestyle. They will share driving experiences, exchange cultural perspectives on aesthetics and explore elegant living across cultures with LEPAS. Their feedback will inform LEPAS’s product, service and brand development.

Throughout the week, LEPAS will bring elegance to life through shared experiences. The LEPAS Global Journey of Elegant Driving and practical demonstrations will showcase composed driving on real roads and the convenience of intelligent technology in everyday situations. The LEPAS All-New Concept Car will offer a vision of future mobility design, while Global Elegance Night will bring together different cultures and personal stories.

Beyond driving experiences, LEPAS seeks to build deeper connections with users and partners worldwide through shared ideas and collaboration. The relationships formed in Wuhu will extend beyond the event, bringing LEPAS’s vision of elegance into everyday life.

About LEPAS

LEPAS is Chery Auto’s Premium NEV brand, dedicated to creating elegant mobility experiences for users worldwide. Committed to becoming the Preferred Brand for Elegant Mobility Life, LEPAS brings together Leopard Aesthetics, Elegant Technology, and Exquisite Space – transforming elegance into a driving experience you can see, feel, and trust. Supported by a growing global dealer network of more than 500 sales and service outlets, LEPAS is expanding its international footprint through localized operations, delivering products and experiences tailored to users across global markets.

Media Contact

Company Name: LEPAS International

Contact Person: Vincy Wang

E-mail: GlobalPR@lepasinternational.com

Company Official Website: https://lepasinternational.com/

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d3ec1b83-abec-42d9-ac19-72c1a8f53777
https://www.globenewswire.com/NewsRoom/AttachmentNg/d660e395-9de2-4df6-9d9e-f9fc5a14429c

HONG KONG, Oct. 20, 2026 (GLOBE NEWSWIRE) — 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider committed to becoming a next-generation artificial intelligence (“AI”) infrastructure solutions provider, today provided an update on its Mikkeli AI compute center project in Finland. Following the Company’s announcement on October 19, 2026 regarding the disclosure of the 9 MVA core grid connection agreement executed on October 13, the Company’s management provides this supplementary disclosure to the capital markets regarding the material impact of this energy asset on the Company’s long-term commercial model. Based on the current industry conditions, this update outlines the strategic and financial implications of this high-capacity connection in helping prevent compute cluster fragmentation, supporting access to clean energy, and facilitating manufacturing schedules for core electromechanical equipment.

Addressing the European FLAP-D Market Capacity Bottleneck: Translating Infrastructure Metrics into Quantifiable Time Advantages

In the current expansion cycle, the deployment of enterprise-grade AI computing capacity faces significant geographical disparities in infrastructure availability. The transmission and distribution grids in established European data center hubs (specifically the FLAP-D markets: Frankfurt, London, Amsterdam, Paris, and Dublin) face structural capacity constraints. Constrained by prolonged environmental approval procedures for substation facility expansions, grid connection waiting periods for new data centers have extended significantly, reducing the predictability of project delivery.

In this supply-demand environment, the on-schedule delivery of underlying physical infrastructure has emerged as a central variable in the research and development cycles of large language models. For leading research enterprises that must secure large-scale computing capacity to develop trillion-parameter and next-generation multi-modal models, delays in infrastructure directly translate into substantial commercial opportunity costs.

Against this backdrop, 3 E Network’s successful acquisition of the substantive access permit to the 20 kV Medium Voltage grid in the Finnish Lake District is expected to help mitigate the macro-infrastructure execution risks for the Mikkeli project. By supporting the planned time-to-market schedule for 2027, the Company may not only enhance the predictability of the compute delivery cycle for clients but also position the project to benefit from infrastructure scarcity within the resource-constrained European market.

The Economics of Compute Density: Centralized Power Supports Network Topology and Single-Run ROI

As the number of parameters in large AI models continues to grow, the requirement for physical contiguity within data centers imposed by underlying hardware architectures becomes increasingly strict. Currently, rack power density for new-generation compute clusters can exceed 100kW. Facing these thermal loads, certain legacy facilities, which are restricted by power capacity and required to adopt distributed room layouts, may experience increasing system integration costs and reduced computing efficiency.

The planned 9 MVA high-capacity centralized power supply is expected to provide 3 E Network with more resilient physical network topology conditions. This layout supports the continuous deployment of high-density enterprise-grade compute clusters within a single, concentrated physical zone, thereby reducing potential East-West data traversal overhead associated with the distribution of computational nodes across different zones.

By reducing the length of high-speed interconnect cables between servers at the physical layer, network latency during large-scale cluster parallel training is systematically optimized. This engineering improvement is intended to directly increase the client’s model training throughput, thereby improving the return on investment (“ROI”) of a single large model training run from a financial forecasting perspective.

Reshaping the Financial Model: Clean Energy Matrix Stabilizes OPEX and Compliance Capabilities Enhance Offtake Agreement Negotiations

Within the operating expenditure (“OPEX”) structure of data centers, the procurement price of electricity is a determining factor for compute leasing gross margins. Supported by Finland’s established hydroelectric and wind power grid matrix, the Mikkeli project establishes a structural hedge against the volatility of global fossil fuel prices, assisting the Company in maintaining a stable and cost-competitive long-term per-kilowatt-hour baseline.

Furthermore, with the implementation of the Corporate Sustainability Reporting Directive (“CSRD”) across the European Union, heavy compute consumer groups, such as multinational financial institutions and large healthcare enterprises, are subject to Scope 2 greenhouse gas emissions reporting requirements. Under this compliance framework, 3 E Network’s “High-Proportion Clean Energy Architecture” serves more than an environmental corporate social responsibility initiative; rather, it transitions into a prerequisite procurement metric for clients to fulfill operational compliance. The strategy of leveraging ESG compliance capabilities to meet customers’ procurement requirements is anticipated to provide the Company with non-price competitive advantages in future long-term compute offtake agreement negotiations.

Optimizing Supply Chain Execution: Supporting Core Capital Expenditure Manufacturing via Confirmed Grid Access

Presently, the global data center electromechanical equipment supply chain broadly faces capacity constraints. Without confirmed grid specifications, significant capital expenditure commitments carry elevated stranded asset risks; simultaneously, lead times for core mechanical, electrical, and plumbing (“MEP”) equipment, including large-scale medium- and low-voltage distribution transformers and heavy-duty backup generators, can extend over multiple years. With the execution of the 9 MVA agreement on October 13, 3 E Network obtained a clearer basis for advancing its subsequent supply chain strategy. The confirmation of grid metrics may help reduce the project’s core execution risks and provides greater capital expenditure visibility for the formulation of detailed equipment procurement plans. Based on defined electrical parameters, the Company is now positioned to place irrevocable orders with leading global suppliers. Through this measure, the Company aims to secure priority manufacturing and delivery schedules for core electromechanical equipment, thereby safeguarding the overall construction progress of the Mikkeli project and establishing a controlled execution pathway to achieve full commercial operation in 2027.

About 3 E Network Technology Group Limited
3 E Network Technology Group Limited is a business-to-business (“B2B”) information technology (“IT”) business solutions provider committed to becoming a next-generation artificial intelligence (“AI”) infrastructure solutions provider. It upholds the industry consensus of “AI and energy symbiosis” and has a strong vision in the field of energy investment. The Company’s business comprises two main portfolios: the data center operation services portfolio and the software development portfolio. For more information, please visit the Company’s website at https://3emask.com/.

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect the Company’s future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

3 E Network Technology Group Limited
Investor Relations Department
Email: ird@3emask.com
Website: https://3emask.com/

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Eleco Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	19/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p Ordinary Shares
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	1,146,420	1.35%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,146,420	1.35%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
1p Ordinary Shares	Sale	1,130	230.1071p

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
1p Ordinary Shares

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	20/10/2026
Contact name:	Lydia Cotterill – Compliance Department
Telephone number:	0151 237 1176

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

ST. LOUIS, Oct. 20, 2026 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 third quarter on Tuesday, November 10, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.

What:	Stereotaxis third quarter 2026 financial results conference call
When:	Tuesday, November 10, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Dial In Number:	To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 2568629.
Webcast:	To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.
Call Replay:	A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here.

About Stereotaxis
Stereotaxis, Inc. (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:                                        
David L. Fischel                                        
Chairman and Chief Executive Officer                        
                                                        
Kimberly Peery                                                
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

Latest investment under Micron’s up to $3 billion U.S. supply-chain plan strengthens the domestic semiconductor ecosystem and expands access to critical materials for advanced memory manufacturing

BOISE, Idaho, Oct. 20, 2026 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU) today announced an investment in critical minerals processing and high-purity materials manufacturing that is expected to support the expansion of Indium Corporation’s capabilities in Central New York, restarting domestic processing of critical minerals essential to advanced semiconductor manufacturing. The investment is part of Micron’s plan, announced in July, to invest up to $3 billion to strengthen the U.S. semiconductor supply-chain ecosystem and secure a reliable domestic supply of critical manufacturing materials.

Under the agreement, Micron will provide strategic funding that enables Indium Corporation to expand its refining and manufacturing operations in Rome, New York. The companies will enter into a long-term supply agreement that gives Micron access to these high-purity minerals. The investment is expected to reduce reliance on concentrated global refining capacity, addressing a growing national security priority.

“Advanced memory manufacturing depends on a reliable supply of critical minerals. Enabling that requires engagements well beyond our direct suppliers,” said Ben Tessone, senior vice president and chief procurement officer at Micron Technology. “Securing these inputs is essential to Micron’s long-term growth and technology roadmap. Partnering with Indium Corporation to restart this capability in its New York facility expands U.S. capacity for critical minerals production and builds a more resilient supply chain for American semiconductor manufacturing and national security.”

“Micron’s decision to partner with Indium Corporation reflects the trust they’ve placed in our people and our ability to deliver,” said Ross Berntson, president and CEO of Indium Corporation. “For more than 90 years, we’ve called Central New York home, developing materials that support some of the world’s most advanced technologies. We’re grateful for Micron’s confidence in our team and the opportunity to build on that history. Together, we’re expanding the supply of semiconductor-grade critical minerals and taking an important step forward for domestic manufacturing.”

The agreement with Indium Corporation complements Micron’s plans to accelerate its U.S. fab and technology investments and increase its expected spend to more than $250 billion through 2035. A stronger domestic materials base, including expanded critical minerals capabilities in the same state as its New York fab complex, helps Micron meet growing demand for memory driven by Super Intelligence.

The announcement coincides with Micron’s annual Supplier Awards event celebrating excellent performance of the company’s top suppliers.

New York Governor Kathy Hochul:
“Micron’s progress in Central New York keeps building. The company is months ahead of schedule on the largest private investment in New York State history in Clay, and now it is teaming up with Indium Corporation, a New York manufacturer for generations, to expand Indium Corporation’s operations in Rome and restart critical minerals processing. Every link in the semiconductor supply chain we bring to New York, especially when it is built by a New York company like Indium Corporation, means more opportunities for families to build careers here, a stronger Upstate economy and a more secure nation.”

U.S. Senator Charles E. Schumer:
“I’ve long said Upstate New York is America’s new semiconductor superhighway, and today that superhighway runs right through Oneida County! When I wrote and passed the CHIPS and Science Act into law, delivering Micron’s historic investment to New York, I promised the semiconductor supply chain following Micron would bring even more investment and jobs to communities from Rome to Syracuse and all across our state. With today’s announced partnership between Micron and Indium Corporation, that is exactly what is happening. By working with homegrown, legacy businesses like Indium Corporation, Micron is creating new demand to expand critical mineral processing here in the U.S., reducing reliance on foreign sources and delivering a brighter future for new jobs and investment in the Mohawk Valley.”

Onondaga County Executive Ryan McMahon:
“The preparation is over and the momentum in Clay is real. Foundations are going in, thousands of workers are headed to the site, and now the supply chain we planned for is starting to follow. A semiconductor cluster doesn’t stop at the county line. When Micron invests in our neighbors in Oneida County, it shows all of Central New York is becoming the place where America’s chip industry gets built.”

Oneida County Executive Anthony J. Picente Jr.:
“Indium Corporation has been a leader in advanced manufacturing for 90+ years and this collaboration with Micron not only strengthens Oneida County’s partnership with Onondaga County, but benefits all of Central New York and the Mohawk Valley. Oneida County has been at the forefront of the semiconductor industry for years and we believe that implementing a regional strategy is the key to solidifying our standing as a global hub for research, development and innovation. What’s good for one, is good for all.”

About Micron Technology, Inc. 
Micron Technology, Inc. is a global leader in semiconductor memory and storage, powering AI and compute-intensive applications from cloud to edge. With a relentless focus on our customers, technology and product leadership, and manufacturing and operational excellence, Micron’s comprehensive portfolio of high-performance DRAM, NAND and NOR solutions deliver the speed, efficiency, and scale today’s workloads demand, accelerating intelligence to enrich life for all. To learn more about Micron Technology, Inc. (Nasdaq: MU), visit micron.com.

About Indium Corporation
Indium Corporation® enables technological advancement through materials science innovation and expertise. We develop, refine, extract, process, engineer, manufacture, recycle, and supply advanced materials solutions for the electronics, semiconductor, thin-film, and thermal management industries. From One Engineer to Another®, we work closely with customers to solve complex materials challenges. Our portfolio includes solders, fluxes, specialty alloys, thermal interface and sintering materials, brazes, and specialty metals and inorganic compounds that include indium, gallium, germanium, and tin. Headquartered in the United States, Indium Corporation serves customers through a global network of manufacturing facilities, technical experts, and sales and support teams.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding Micron’s investment plans, future supply arrangements, future demand, and the expected benefits of its investments, including with respect to Micron’s manufacturing operations and the expansion and resiliency of the U.S. semiconductor supply chain. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially. Please refer to the documents Micron files with the Securities and Exchange Commission, specifically its most recent Form 10-K and Form 10-Q. These documents contain and identify important factors that could cause actual results to differ materially from those contained in these forward-looking statements. These certain factors can be found at https://investors.micron.com/risk-factor. Although Micron believes that the expectations reflected in the forward-looking statements are reasonable, Micron cannot guarantee future results, levels of activity, or achievements. Micron is under no duty to update any of the forward-looking statements after the date of this press release to conform these statements to actual results.

© 2026 Micron Technology, Inc. All rights reserved. Information, products, and/or specifications are subject to change without notice. Micron, the Micron logo, and all other Micron trademarks are the property of Micron Technology, Inc. All other trademarks are the property of their respective owners. 

Micron Media Relations Contact
Mark Plungy
Micron Technology, Inc.
+1 (408) 203-2910
corpcomms@micron.com 

Micron Investor Relations Contact
Satya Kumar
Micron Technology, Inc.
+1 (408) 450-6199
satyakumar@micron.com